But also yields more satisfied patients.

Unique comparative study Aiming at acquiring the lead in research and execution is the Centre for Person-Centred Treatment at the Sahlgrenska Academy and the University of Gothenburg. GPCC experts have conducted a unique comparative study with 123 sufferers who were treated based on the person-centred care principle. The purpose of the study was to evaluate if person-centred caution can shorten individuals’ hospital stay, if it enhances their daily functional capacity and quality of life and if it decreases their re-admission rate. Related StoriesFirst medical center installs Ortho Eyesight AnalyzerHeart of the Rockies Regional Medical Center selects Aprima EHRBoston Kids's and Rock Health synergy to accelerate advancement of pediatric health technologiesHospital stay shortened by one-third The results show that the hospital stay for patients who all undergo person-centred treatment is reduced by 2.5 days.‘This demonstrates widespread self-confidence in Aclasta, which provides physicians and patients with a totally new way to control osteoporosis. The initial once-yearly dosing of this medicine has the potential for significant compliance benefits and improved quality of life for females with osteoporosis.’ Unlike oral bisphosphonate therapies taken daily, monthly or weekly, Aclasta is given as a once-yearly 15-minute intravenous infusion. This means with a single treatment, an individual can receive a full year’s security against the effects of osteoporosis. Data display that more than 70 percent of sufferers prefer a once-annual infusion of Aclasta to a weekly tablet[4,5].